Date: Friday, April 7, 2017  
Time: 10.00am  
At: [redacted]  
Subject: AWERB Standing Sub-Group Committee Minutes

Present: [redacted]

Apologies: [redacted]

MINUTES

1. Project Licences  
   a) Amendment: [redacted]  
   The committee discussed the following:  
   • Revise typographical errors in NTS  
   • Explanation for increase of animal numbers  
   • Clarification of estimated numbers under protocol 6  
   • Revise wording under Project Plan: Part D  
   • Inclusion and clarification of the word “niche” in the NTS

2. Minutes of AWERB Committee 29/03/17  
   Minutes were approved.

3. Retrospective reviews  
   a) [redacted]  
   The committee recommend that when preparing a new licence; consider the likely impact of vaccination against cervical cancer on the future direction and benefit of your research. The committee took into consideration the 3Rs committee comments and discussed the following:  
   • Typographical error under section 3.3  
   • Clarify Yes/No for some sections  
   • Numbers error in Protocol 2 Section 3.1  
   • More information on variance in the age of manifestation of the phenotype in one transgenic line and consider publishing this finding  
   • Further explanation under 3Rs Reduction

   b) [redacted] declared a potential conflict of interest. The committee took into consideration the 3Rs committee comments and discussed the following:  
   • Clarification of the meaning of the word “con-specifics”  
   • Use of animals that have a cough
• More information for Section 4.2
• Who has access to the tissue bank
• Reconsider the answer provided in Section 4.9

c) The committee took into consideration the 3Rs committee comments and discussed the following:
• Clarify abbreviations in Section 1.3 and make it clear what happened to the animal and when
• Proof read some sections and remove complex sentences
• Refinement to UVB treatment under Section 4.4
• Removal of references that are not related to current Project Licence
• Animal numbers under Section 3.1
• Permission to more widely disseminate refinement information under section 4.4
• Move answers 3 and 4 in reduction section to refinement section with more explanation
• Recommending more information on post mortem submission in condition 18 reports in future
• Offering AWERB support if requested to address recurring problem resulting in elevated severity and adverse effects following the administration of cells by the intravenous route

4. Any other business
   Nothing to report.

5. Date of next meeting: Wednesday 26th April 2017